SABCS: Combining ribociclib with hormone therapy improved patient outcomes in early-stage breast cancer
ABSTRACT: GA03-03
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease-free survival (iDFS) benefits in patients with early-stage hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer at risk of disease recurrence. Results from the Phase III NATALEE trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented...
SABCS: Studies suggest novel targeted therapies may benefit patients with metastatic HR+/ HER2- breast cancer
ABSTRACTS: RF01-04 and RF01-07
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical...